Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [212Pb]Pb-MP0712
Pb-MP0712 · 1 trial · 7 indications
Type, frequency and severity of adverse events (AEs), and serious adverse events (SAEs), Adverse events of special interest (AESI) and Dose Limiting Toxicities (DLT) using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
Frequency and duration of dose changes
Incidence of dose limiting toxicities
Objective Response Rate (ORR) in the expansion phase ORR is defined as the percentage of patients with partial response (PR) or complete response (CR) as per RECIST v1.1
| Arm | Type | Description |
|---|---|---|
| [203Pb]Pb-DOTAM-MAM279/[212Pb]Pb-DOTAM-MAM279 | EXPERIMENTAL | Patients will receive \[203Pb\]Pb-DOTAM-MAM279 for Imaging/Dosimetry followed by \[212Pb\]Pb-DOTAM-MAM279 for treatment |
| Name | Type | Description |
|---|---|---|
| [212Pb]Pb-MP0712 | DRUG | Radioligand Therapy |
| [203Pb]Pb-MP0712 | OTHER | Radioligand Imaging Agent |
Key Inclusion Criteria: * Age ≥ 18 years old * Histologically or cytologically confirmed: I. advanced extensive or limited SCLC or LC NECs of the lung * SCLC (extensive stage, or limited stage) patients with progression or recurrence following at least two prior line of systemic platinum based t...
Pb-MP0712 is an investigational small molecule radiopharmaceutical developed by Molecular Partners AG for DLL3 expressing solid tumors, including large cell neuroendocrine carcinoma. It is being studied in a Phase 1 clinical trial and has not been approved by the FDA.
Pb-MP0712 is being evaluated for the treatment of large cell neuroendocrine carcinoma and other DLL3 expressing solid tumors, such as small cell lung cancer, extrapulmonary neuroendocrine carcinoma, and gastroenteropancreatic neuroendocrine carcinoma. It is an investigational therapy and is not yet approved for any indication.
Pb-MP0712 targets delta-like ligand 3, also known as DLL3, a protein expressed on the surface of certain neuroendocrine tumors. The drug is designed to deliver radiation to DLL3 expressing cancer cells.
Pb-MP0712 is being developed by Molecular Partners AG, a biopharmaceutical company listed on the SIX Swiss Exchange under the ticker MOLN. The company is conducting a Phase 1 trial of the drug in the United States.
Pb-MP0712 is in Phase 1 clinical development. The ongoing trial is recruiting participants and has an estimated enrollment of 138 patients. The drug is investigational and has not received FDA approval.
Pb-MP0712 is being studied in a Phase 1 clinical trial, NCT07278479, titled Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors. The trial is recruiting in the United States and includes conditions such as large cell neuroendocrine carcinoma and small cell lung cancer.
Yes, Pb-MP0712 is also known as [212Pb]Pb-MP0712. The bracketed notation indicates the radioisotope lead-212 used in the drug. Both names refer to the same investigational compound.